Descrizione del progetto
Sforzo multidisciplinare coordinato per sviluppare una terapia contro i focolai di coronavirus
La risposta alla pandemia da SARS-CoV-2 e ai futuri focolai di coronavirus richiede uno sforzo organizzato e la rapida traslazione delle scoperte scientifiche ai partner industriali. Il progetto MAD-CoV 2, finanziato dall’UE, ha riunito un team multidisciplinare di ricercatori e partner industriali innovativi per studiare le infezioni da virus nelle cellule ospiti e traslare rapidamente le conoscenze in nuovi farmaci e misure di salute pubblica. L’enzima di conversione dell’angiotensina 2 (ACE2) è un promettente bersaglio farmacologico per il trattamento delle malattie cardiovascolari e funge anche da punto di accesso cellulare per alcuni coronavirus. Gli obiettivi di MAD-CoV 2 sono scoprire il ruolo dell’ACE2 nella replicazione virale e nella patogenesi della Covid-19 e traslare questa conoscenza in nuove terapie per combattere i focolai di coronavirus. Il progetto svilupperà inoltre nuove strategie per lo sviluppo di antivirali contro il SARS-CoV2 e altre malattie virali emergenti.
Obiettivo
The SARS-CoV-2 pandemic has become an unprecedented burden to public health, our civil societies and the global economy. To provide frontline therapies for COVID-19 and future corona virus outbreaks requires a concerted effort of different disciplines, technologies, high security labs, and rapid translation of scientific findings to highly innovative and “hungry” SME partners. For the MAD-CoV-2 project we have assembled a multidisciplinary team of world-leading researchers and innovative industry partners to unlock the Achille’s heels of the virus infections in host cells and rapidly translate such knowledge into disruptive new medicines and public health measures. Our team members have been on the ground of the first SARS and Ebola outbreaks, head containment facilities to study highly infectious viruses, are world-leading in engineering human tissues, developed breakthrough technologies that allow us to find host factors for viral infections at unmatched speed and resolution, and discovered ACE2 and made the first in vivo link between ACE2, SARS, and lung injury, leading to rational drug development which is imminent to be tested in European COVID-19 patients. ACE2 is also the key receptor for SARS-CoV-2 Spike protein and has got centre stage for novel therapies and a fundamental understanding of COVID-19. The aims of MAD-CoV-2 are 1. to engineer human tissues to test novel therapies and vaccines; 2. to provide critical evidence on the role of clinical grade ACE2 in viral replication and COVID-19 pathogenesis; 3. to perform high-throughput screens to genetically map, at a single amino acid resolution, essential host factor that are critical for SARS-CoV-2 replication; and 4. to rapidly translate this knowledge into novel therapies to fight the current and, importantly, future corona virus outbreaks.
Our data and unique tissue reagents will be made available to the entire community for drug testing and development, supporting all other efforts.
Campo scientifico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesebola
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantivirals
Parole chiave
Programma(i)
Argomento(i)
Invito a presentare proposte
H2020-JTI-IMI2-2020-21-single-stage
Vedi altri progetti per questo bandoMeccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
75189 Uppsala
Svezia